Product Images Finasteride

This is a description of Finasteride 5mg tablets in a quantity of 90 tablets. The medication is for prescription (RX ONLY) and the source NDC is 57237-0062-05. It is manufactured by Rising Pharma, Inc. in Allendale, NJ. The medication should be kept out of reach of children, and it is specifically advised that women and children should not use Finasteride. The directions for use can be found in the package insert. The medication should be stored at 20-25°C (58-77°F) with excursions permitted to 15-30°C (59-86°F) as per USP standards. This batch has been repackaged by RemedyRepack Inc. in Indiana, PA.*

This text provides a mean change from baseline with 1 standard error (SE) in a study evaluating the symptom score in two long-term efficacy and safety studies comparing a placebo group against a finasteride group over the course of four years. The data presented includes symptom scores at baseline, year 1, year 2, year 3, and year 4. This information can be used to assess the effects of finasteride treatment on symptom scores over time.*

This text provides statistical data on the percent of patients undergoing surgery for BPH with and without the use of Finasteride, over a period of 48 months. The figure shows the observed percentage of patients at different time intervals, with the number of patients at risk and events in both the Finasteride and Placebo groups.*

Figure 3 shows the percentage of patients developing acute urinary retention over time in both the Finasteride and Placebo groups. The data is presented based on observation time in months for each group. The Placebo group had higher percentage of patients developing acute urinary retention compared to the Finasteride group. It also provides information on the number of events and number at risk per year for each group.*

This text provides data on the mean percent change from baseline with 1 standard error in a long-term efficacy and safety study related to prostate volume. The study includes placebo and finasteride groups with prostate volume measurements at baseline, year 1, year 2, year 3, and year 4. The values for these measurements are also provided in the form of a table.*

This is a graph showing the cumulative incidence of a 4-point rise in AUA Symptom Score by treatment group over time, measured in years from randomization. The percentage of individuals experiencing this increase in symptoms is displayed on the y-axis, while the x-axis represents the years since randomization.*